Neuland Laboratories Receives Administrative Caution from SEBI for Insider Trading Breach

Pharmaceutical company Neuland Laboratories Ltd announced on Tuesday (June 17) that it has received an administrative warning letter from the Securities and Exchange Board of India (SEBI) concerning a breach of insider trading regulations by a designated individual associated with the company.

The warning, dated June 13 and acknowledged on June 17, 2025, was issued by SEBI’s Deputy General Manager. This violation relates to failure to comply with pre-clearance requirements as stipulated in the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The net profit for the period dropped by 59% year-on-year to ₹27.8 crore. The quarterly revenue was recorded at ₹328 crore, reflecting a 15% decrease from ₹385 crore reported in the same quarter last year. Neuland’s EBITDA for this quarter declined 52% compared to the previous year, amounting to ₹51.1 crore, with margins contracting to 16% from 27.8% in the previous fiscal year.

The company experienced a reduction in total revenue in FY25 compared to FY24. Additionally, operating margins declined in accordance with initial expectations for the fiscal year. CMS revenues reached ₹637 crore, primarily driven by commercial-stage molecules. Despite the revenue downturn, the customer base has expanded.

Neuland Laboratories anticipates a revival in its growth trajectory in FY26 and maintains a positive outlook for both its short- and long-term growth prospects.

Shares of Neuland Laboratories Ltd closed at ₹12,600.00, down by ₹236.85, or 1.85%, on the BSE.